Composition and uses thereof
US-2016144011-A1 · May 26, 2016 · US
Treatment and prevention of malaria
US9603916B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9603916-B2 |
| Application number | US-201514936309-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2015 |
| Priority date | Feb 25, 2011 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A viral vector or DNA plasmid that expresses PfRH5 antigen having at least 95% sequence identity with SEQ ID NO:2, wherein said PfRH5 antigen lacks the N-terminal signal peptide of PfRH5, wherein the N-terminal signal peptide corresponds to amino acid residues 1 to 25 of SEQ ID NO: 1. 2. A viral vector or DNA plasmid that expresses PfRH5 antigen having at least 95% sequence identity with amino acid residues 34 to 534 of SEQ ID NO:2, wherein said PfRH5 antigen lacks amino acid residues 1 to 25 of SEQ ID NO: 1. 3. The viral vector or DNA plasmid of claim 1 , wherein the viral vector or DNA plasmid expresses one or more antigens selected from the group consisting of PfAMA1, PfEBA175, PfRH2a, PfRH2b and PfRH4. 4. The viral vector or DNA plasmid of claim 1 , in combination with a viral vector or DNA plasmid that expresses one or more antigens selected from the group consisting of PfAMA1, PfEBA175, PfRH2a, PfRH2b and PfRH4. 5. The viral vector of claim 1 , wherein the viral vector is a human or simian adenovirus, or a pox virus. 6. The viral vector of claim 5 , wherein the viral vector is an AdHu5, AdCh63 or modified vaccinia Ankara (MVA) vector. 7. The DNA plasmid of claim 1 , wherein the DNA vector is capable of expression in a mammalian expression system. 8. A vaccine composition comprising the vector and/or DNA plasmid of claim 1 . 9. The vaccine composition of claim 8 , further comprising an additional viral vector or DNA plasmid that expresses one or more antigens selected from the group consisting of PfAMA1, PfEBA175, PfRH2a, PfRH2b and PfRH4.
Assignees
Inventors
Classifications
Antimalarials · CPC title
Aptamers · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Use of virus, viral particle or viral elements as a vector · CPC title
Comprising a combination of two or more separate antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9603916B2 cover?
- There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector tha…
- Who is the assignee on this patent?
- Isis Innovation, Univ Oxford Innovation Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K39/015. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).